Scribd
Upload
52 views

Definition of Cardiotoxicity Antineoplastic Drugs and Cardiomyopathy 1

This document discusses cardiotoxicity caused by various antineoplastic drugs and defines two main types of drug-induced cardiomyopathy - Type I caused by anthracyclines and Type II caused by trastuzumab. It describes the short-term and long-term effects of Type I agents as well as risk factors and pathophysiological mechanisms. For Type II agents, it covers risk factors and mechanisms including interaction with anthracyclines. The document also briefly mentions other cardiotoxic effects, strategies to limit toxicity, and techniques for monitoring cardiotoxicity in clinical practice.

Uploaded by

Laureano Gomez Zabala
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as DOCX, PDF, TXT or read online on Scribd
52 views

Definition of Cardiotoxicity Antineoplastic Drugs and Cardiomyopathy 1

This document discusses cardiotoxicity caused by various antineoplastic drugs and defines two main types of drug-induced cardiomyopathy - Type I caused by anthracyclines and Type II caused by trastuzumab. It describes the short-term and long-term effects of Type I agents as well as risk factors and pathophysiological mechanisms. For Type II agents, it covers risk factors and mechanisms including interaction with anthracyclines. The document also briefly mentions other cardiotoxic effects, strategies to limit toxicity, and techniques for monitoring cardiotoxicity in clinical practice.

Uploaded by

Laureano Gomez Zabala
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as DOCX, PDF, TXT or read online on Scribd
You are on page 1/ 1

Introduction

Definition of cardiotoxicity
Antineoplastic drugs and cardiomyopathy

Type I agents: anthracyclines


Short- and long-term cardiotoxic effects
Risk factors
Pathophysiological mechanisms 2
Strategies to limit cardiotoxicity

Type II agents: trastuzumab


Risk factors
Pathophysiological mechanisms 3
a)

Anthracyclines, hypoxia, oxidative stress

b) Anthracyclines, hypoxia, oxidative stress


Cardiotoxicity of concomitant trastuzumab and anthracyclines 4
Figure 2 Interaction of the cardiotoxic mechanisms of anthracyclines with those of trastuzumab.

Strategies to limit cardiotoxicity 5

Other cardiotoxic effects


Myocardial ischemia

Arrhythmias
Systemic hypertension
Thromboembolism

Cardiotoxicity associated with radiotherapy 6


Table 4 Cardiotoxicity of the main classes of cancer drugs used in clinical practice. 7 (2 hojas)
Table 5 Advantages and disadvantages of the principal techniques used for monitoring cardiotoxicity in clinical
practice. 8 (2 hojas)

Testing and monitoring -- Preclinical testing 8


Monitoring and early detection 8

Conclusion 9
Ethical disclosures

You might also like